Paper Details

  1. Home
  2. Paper Details

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate for Nonoccupational HIV-1 Postexposure Prophylaxis: A Prospective Open-Label Trial (DORAVIPEP).

Author: , AmbrosioniJuan, BarreroLaura, BerrocalLeire, BlancoJosé Luis, CallauPilar, ChiviteIván, De LazzariElisa, De la MoraLorena, FernándezEmma, González-CordónAna, InciarteAlexy, LagunoMontserrat, MallolasJosep, MartínezEsteban, Martínez-RebollarMaría, RicoVerónica, SolbesEstela, TorresBerta, UgarteAinoa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This prospective, open-label, single-arm trial evaluated the single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). Noncompletion of PEP was 29% and 20% per modified intention-to-treat. The main reasons for noncompletion were loss to follow-up and intolerance. The study concludes that DOR/3TC/TDF is a well-tolerated option for nonoccupational PEP.
Paper Details　
Original Abstract of the Article :
BACKGROUND: New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For this reason, we evaluated the single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for 28...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394723/

データ提供：米国国立医学図書館（NLM）

Evaluating a New Regimen for Nonoccupational HIV-1 Postexposure Prophylaxis

Nonoccupational HIV-1 postexposure prophylaxis (PEP), a crucial intervention to prevent HIV infection following potential exposure, is undergoing a transformation.

This prospective, open-label trial investigated the efficacy and safety of a single-tablet regimen of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) for PEP.

DOR/3TC/TDF: A Well-Tolerated Option for PEP

The researchers enrolled 399 individuals who had experienced potential HIV-1 exposure within 72 hours. The results showed that DOR/3TC/TDF was generally well-tolerated, with noncompletion of PEP primarily due to loss to follow-up.

A Promising New Regimen for PEP

This study provides encouraging evidence that DOR/3TC/TDF is a well-tolerated and potentially effective option for nonoccupational PEP.

Dr. Camel's Conclusion

This research offers a promising step forward in the quest for effective and convenient PEP regimens. The DOR/3TC/TDF single-tablet regimen, like a refreshing oasis in the desert of HIV prevention, presents a potential solution to improve adherence and access to PEP, ultimately contributing to the fight against HIV.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-09-02
Further Info :

Pubmed ID

37539061

DOI: Digital Object Identifier

PMC10394723

Related Literature

Article Analysis
・Effects of doravirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.